title: Genome-wide profiling reveals transcriptional repression of MYC as a core component of NR4A tumor suppression in acute myeloid leukemia.
abstract: Acute myeloid leukemias (AMLs) are a heterogeneous group of diseases that are sustained by relatively rare leukemia-initiating cells (LICs) that exhibit diverse genetic and phenotypic properties. AML heterogeneity presents a major challenge to development of targeted therapies, and effective treatment will require targeting of common molecular drivers of AML maintenance. The orphan nuclear receptors NR4A1 and NR4A3 are potent tumor suppressors of AML. They are silenced in all human AML LICs, irrespective of patient cytogenetics, and their deletion in mice leads to postnatal AML development. In the current report, we address the tumor-suppressive mechanisms and therapeutic potential of NR4As for AML intervention. We show that rescue of either NR4A1 or NR4A3 inhibits the leukemogenicity of AML cells in vivo and reprograms a subset of gene signatures that distinguish primary human LICs from normal hematopoietic stem cells (HSCs), irrespective of subtype. Central to NR4A reprogramming is the acute suppression of an LIC submodule that includes the transcriptional repression of MYC. Additionally, we show that upregulation of MYC is an acute preleukemic consequence of NR4A deletion and that MYC suppression functionally contributes to NR4A antileukemic effects. Collectively, these results identify NR4As as novel targets for AML therapeutic intervention and reveal molecular targets of NR4A tumor suppression, including the suppression of MYC.
authors.affiliation: Interdepartmental Program in Cell and Molecular Biology, Baylor College of Medicine, Houston, TX, USA.
authors.forename: S P
authors.initials: SP
authors.lastname: Boudreaux
authors.forename: A M
authors.initials: AM
authors.lastname: Ramirez-Herrick
authors.forename: R P
authors.initials: RP
authors.lastname: Duren
authors.forename: O M
authors.initials: OM
authors.lastname: Conneely
references.citation: J Exp Med. 1996 Aug 1;184(2):465-72
references.pmid: 8760800
references.citation: Science. 1995 Jul 28;269(5223):532-5
references.pmid: 7624775
references.citation: Cancer Cell. 2006 Mar;9(3):175-87
references.pmid: 16530702
references.citation: Nucl Recept Signal. 2006;4:e002
references.pmid: 16604165
references.citation: Nature. 2011 Jan 20;469(7330):356-61
references.pmid: 21160474
references.citation: Blood. 2009 Dec 24;114(27):5499-511
references.pmid: 19855079
references.citation: Nature. 2011 Jan 20;469(7330):362-7
references.pmid: 21248843
references.citation: Blood. 2005 Nov 1;106(9):2982-91
references.pmid: 16076868
references.citation: Semin Cancer Biol. 2010 Apr;20(2):71-6
references.pmid: 20026405
references.citation: J Biol Chem. 2007 Mar 30;282(13):9492-9504
references.pmid: 17283078
references.citation: Blood. 2002 Sep 1;100(5):1532-42
references.pmid: 12176867
references.citation: Methods Enzymol. 2006;411:134-93
references.pmid: 16939790
references.citation: Endocrinology. 2007 Jan;148(1):34-44
references.pmid: 17023523
references.citation: Nat Cell Biol. 2010 Dec;12(12):1213-9
references.pmid: 21076412
references.citation: Nature. 1994 Jan 20;367(6460):281-4
references.pmid: 8121494
references.citation: Cell. 2009 Apr 3;137(1):47-59
references.pmid: 19345186
references.citation: Nat Immunol. 2011 Jul 03;12(8):778-85
references.pmid: 21725321
references.citation: Cell. 2007 Jan 26;128(2):325-39
references.pmid: 17254970
references.citation: Cell Stem Cell. 2011 Sep 2;9(3):262-71
references.pmid: 21885021
references.citation: Blood. 2009 Nov 5;114(19):3976-7
references.pmid: 19892722
references.citation: Science. 2009 Jun 26;324(5935):1670-3
references.pmid: 19556499
references.citation: Nat Med. 2007 Jun;13(6):730-5
references.pmid: 17515897
references.citation: Biotechniques. 2003 Feb;34(2):374-8
references.pmid: 12613259
references.citation: Blood. 2008 Dec 15;112(13):4793-807
references.pmid: 19064739
references.citation: Nature. 1994 Jan 20;367(6460):277-81
references.pmid: 8121493
references.citation: Cell. 2004 Feb 20;116(4):527-40
references.pmid: 14980220
references.citation: Proc Natl Acad Sci U S A. 2004 Oct 19;101(42):15231-6
references.pmid: 15477587
references.citation: Nat Rev Genet. 2011 Mar;12(3):154
references.pmid: 21263447
references.citation: Blood. 2005 Oct 1;106(7):2452-61
references.pmid: 15972450
references.citation: Hematology Am Soc Hematol Educ Program. 2004;:80-97
references.pmid: 15561678
references.citation: Oncogene. 2009 Mar 5;28(9):1274-9
references.pmid: 19137012
references.citation: Cell Stem Cell. 2010 Nov 5;7(5):618-30
references.pmid: 20888316
references.citation: Best Pract Res Clin Haematol. 2007 Mar;20(1):13-8
references.pmid: 17336250
references.citation: Cell. 2010 Oct 15;143(2):313-24
references.pmid: 20946988
references.citation: Best Pract Res Clin Haematol. 2009 Dec;22(4):483-7
references.pmid: 19959097
references.citation: Cell. 2009 Sep 4;138(5):822-9
references.pmid: 19737509
references.citation: Mol Cell. 1999 Aug;4(2):199-207
references.pmid: 10488335
references.citation: Genes Dev. 2011 Aug 1;25(15):1628-40
references.pmid: 21828272
references.citation: Mol Cell Biol. 2004 Apr;24(7):2890-904
references.pmid: 15024077
references.citation: Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3396-401
references.pmid: 19218430
references.citation: Blood. 2009 Mar 19;113(12):2661-72
references.pmid: 19168794
references.citation: Blood. 2011 Mar 3;117(9):2681-90
references.pmid: 21205929
references.citation: FEBS Lett. 2004 Aug 27;573(1-3):83-92
references.pmid: 15327980
references.citation: Blood. 2006 Jul 1;108(1):337-45
references.pmid: 16527891